Analysts expect BIONDVAX PHARMA/S (NASDAQ:BVXV) to post earnings per share of ($0.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S reported earnings per share of ($0.59) during the same quarter last year, which would indicate a positive year over year growth rate of 98.3%. The company is expected to announce its next earnings report on Monday, April 29th.

According to Zacks, analysts expect that BIONDVAX PHARMA/S will report full-year earnings of ($0.05) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.04) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last announced its quarterly earnings results on Wednesday, August 22nd. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($1.11).

Separately, ValuEngine upgraded BIONDVAX PHARMA/S from a “sell” rating to a “hold” rating in a research report on Tuesday, October 2nd.

Shares of BIONDVAX PHARMA/S stock opened at $5.90 on Monday. The company has a market capitalization of $36.23 million, a price-to-earnings ratio of -2.98 and a beta of 0.97. BIONDVAX PHARMA/S has a one year low of $4.60 and a one year high of $7.71. The company has a debt-to-equity ratio of 2.95, a quick ratio of 20.74 and a current ratio of 20.74.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

Featured Story: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on BIONDVAX PHARMA/S (BVXV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.